Therapeutic Area: Oncology

Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100

Morrow et al.
Molecular Therapy — Oncolytics
Papers
September 2016
Authors and Affiliates
Matthew P Morrow1, Kimberly A Kraynyak1, Albert J Sylvester1, Xuefei Shen1, Dinah Amante1, Lindsay Sakata1, Lamar Parker2, Jian Yan1, Jean Boyer1, Christian Roh1, Laurent Humeau1, Amir S Khan1, Kate Broderick1, Kathleen Marcozzi-Pierce1, Mary Giear1, Jessica Lee1, Cornelia L Trimble3, J Joseph Kim1, Niranjan Y Sardesai1, David B Weiner4 and Mark L Bagarazzi1 1 Inovio Pharmaceuticals, Plymouth Meeting, Pennsylvania, USA; 2 Unified Women’s Clinical Research, Winston-Salem, North Carolina, USA; 3 Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; 4 The Wistar Institute, Philadelphia, Pennsylvania, USA

Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient

Bernal-Estéve et al.
BMC Cancer
Papers
August 2016
Authors and Affiliates
David Bernal-Estévez 1,2 , Ramiro Sánchez 3 , Rafael E. Tejada 4 and Carlos Parra-López 1,5 1Immunology and Traslational Medicine Research Group, Graduated School in Biomedical Sciences, Department of Microbiology, Medical School, Universidad Nacional de Colombia, Carrera 30 #45-03 Building 471, office 304, Bogotá, Colombia South-America. 2Immunology and Clinical Oncology Bernal-Estévez et al. BMC Cancer (2016) 16:591 Page 12 of 13 Research Group (GIIOC), Fundación Salud de los Andes, Calle 44 No. 58-05, Bogotá, Colombia South-America. 3Clínica del Seno, Carrera 11 # 68-36, Bogotá, Colombia South-America. 4Hospital Occidente de Kennedy E.S.E., Servicio de Oncología, Bogotá, Colombia South-America. 5 Facultad de Medicina, Departamento de Microbiología, Universidad Nacional de Colombia, Carrera 30 Calle 45, Bogotá, Colombia.

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Wallin et al.
Nature Communications
Papers
August 2016
immuneAccess
Authors and Affiliates
Jeffrey J. Wallin1, Johanna C. Bendell2, Roel Funke1, Mario Sznol3, Konstanty Korski4, Suzanne Jones2, Genevive Hernandez1, James Mier5, Xian He1, F. Stephen Hodi6, Mitchell Denker1, Vincent Leveque1, Marta Canamero4, Galina Babitski4, Hartmut Koeppen1, James Ziai1, Neeraj Sharma1, Fabien Gaire4, Daniel S. Chen1, Daniel Waterkamp1, Priti S. Hegde1 & David F. McDermott5 1 Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA. 2 GI Oncology Research, Drug Development Unit, Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, Tennessee, 37203, USA. 3 Department of Internal Medicine and Melanoma Unit, Yale Cancer Center, New Haven, Connecticut 06511, USA. 4 Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg, Germany. 5 Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusets 02215, USA. 6 Dana-Farber/Brigham and Women’s Cancer Center, 450 Brookline Avenue, Boston, Massachusets 02215, USA.

Tumor- and neoantigen-reactive T-cell receptors can be identified based on their frequency in fresh tumor

Pasetto et al.
Cancer Immunology Research
Papers
July 2016
Authors and Affiliates
Anna Pasetto1 , Alena Gros1 , Paul F Robbins1 , Drew C Deniger1 , Todd D Prickett1 , Rodrigo Matus-Nicodemos2,3 , Daniel C Douek3 , Bryan Howie4 , Harlan Robins4,5 , Maria R Parkhurst1 , Jared Gartner1 , Katarzyna Trebska-McGowan1 , Jessica S Crystal1 , Steven A Rosenberg1 * 1Surgery Branch, National Cancer Institute, National Institutes of Health (NIH), Bethesda, Maryland, USA, 2Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD 20892, USA, 3Human Immunology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA, 4Adaptive Biotechnologies, Seattle, WA 98102, USA, 5Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer

Sridharan et al.
British Journal of Cancer
Papers
July 2016
Authors and Affiliates
Vishwajith Sridharan1,2, Danielle N Margalit1, Stephanie A Lynch1, Mariano Severgnini3, Jun Zhou3, Nicole G Chau4, Guilherme Rabinowits4, Jochen H Lorch4, Peter S Hammerman4, F Stephen Hodi3,4, Robert I Haddad4, Roy B Tishler1 and Jonathan D Schoenfeld1 1Department of Radiation Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Center, Boston, MA, USA; 2Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA, USA; 3Center for Immuno-oncology, Dana-Farber Cancer Institute, Boston, MA, USA and 4Department of Medical Oncology, Brigham and Women’s Hospital/Dana-Farber Cancer Center, Boston, MA, USA

Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor

Caruso et al.
Journal of Immunotherapy
Papers
June 2016
Authors and Affiliates
Hillary G. Caruso,1,5 Hiroki Torikai,1 Ling Zhang,1 Sourindra Maiti,1 Jianliang Dai,2 Kim-Anh Do,2 Harjeet Singh,1 Helen Huls,1 Dean A. Lee,1,5 Richard E. Champlin,4 Amy B. Heimberger,3 and Laurence J.N. Cooper1,5 1Division of Pediatrics; Departments of 2Biostatistics; 3Neurosurgery; 4Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center; and 5The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX.

Next-generation IgVH sequencing CLL-like monoclonal B-cell lymphocytosis reveals frequent oligoclonality and ongoing hypermutation

Klinger et al.
Papers
May 2016
Authors and Affiliates
Mark Klinger1, Jianbiao Zheng1, Kojo S. Elenitoba-Johnson2, Sherrie L. Perkins3, Malek Faham1 and David W. Bahler3 1Sequenta, Inc., South San Francisco, CA, 2Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, 3Department of Pathology, ARUP Laboratories, University of Utah, Salt Lake City, UT

Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient

Chapuis et al.
Journal of Experimental Medicine
Papers
May 2016
Authors and Affiliates
Aude G. Chapuis,1 Sylvia M. Lee,1 John A. Thompson,2 Ilana M. Roberts,1 Kim A. Margolin,2 Shailender Bhatia,2 Heather L. Sloan,1 Ivy Lai,1 Lelecia Wagener,1 Kendall Shibuya,1 Jianhong Cao,1 Jedd D. Wolchok,3 Philip D. Greenberg,1,4 and Cassian Yee1 1Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA 98109, 2Division of Medical Oncology, Department of Medicine, University of Washington Medical, Center/FHCRC/Seattle Cancer Care Alliance, Seattle, WA 98109, 3Ludwig Center, Memorial Sloan-Kettering Cancer Center, New York, NY 100165, 4Department of Immunology, University of Washington School of Medicine, Seattle, WA 9819

Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects

Sheikh et al.
Cancer Research
Papers
May 2016
Authors and Affiliates
Sheikh NA1, Cham J2, Zhang L3, DeVries T1, Letarte S4, Pufnock J1, Hamm D5, Trager JB1, Fong L6. 1Research, Dendreon. 2Department of Medicine, University of California, San Francisco. 3Medicine, University of California, San Francisco. 4Bioanalytical Sciencies, Hospira. 5Adaptive Biotechnologies. 6Department of Medicine, University of California, San Francisco